Matrix metalloproteinase-9, tissue inhibitor of metalloproteinase-1, B + tenascin-C and ED-A+ fibronectin in dilated cardiomyopathy: Potential impact on disease progression and patients' prognosis

International Journal of Cardiology

Volumn 168, Issue 6, 2013, Pages 5344-5351

  Franz, Marcus ^a   Berndt, Alexander ^a   Neri, Dario ^b   Galler, Kerstin ^a   Grün, Katja ^a   Porrmann, Christiane ^a   Reinbothe, Franziska ^a   Mall, Gerhard ^c   Schlattmann, Peter ^a   Renner, André ^d   Figulla, Hans Reiner ^a   Jung, Christian ^a   Küthe, Friedhelm ^a  

^a JENA UNIVERSITY HOSPITAL   (Germany)

^b ETH ZURICH   (Switzerland)

^c KLINIKUM DARMSTADT   (Germany)

^d RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

Dilated cardiomyopathy; Fibronectin; MMP 9; Prognosis; Tenascin C; TIMP 1

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRONECTIN; GELATINASE B; TENASCIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ADULT; ARTICLE; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; DISEASE COURSE; FEMALE; HEART MUSCLE BIOPSY; HEART TRANSPLANTATION; HIGH RISK POPULATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RISK ASSESSMENT; SURVIVAL; SURVIVAL RATE; TISSUE LEVEL; TRANSPLANTATION FREE SURVIVAL;

DILATED CARDIOMYOPATHY; FIBRONECTIN; MMP-9; PROGNOSIS; TENASCIN-C; TIMP-1;

ADULT; BIOLOGICAL MARKERS; BIOPSY; CARDIOMYOPATHY, DILATED; DISEASE PROGRESSION; EXTRACELLULAR MATRIX; FEMALE; FIBRONECTINS; FIBROSIS; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; MALE; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; MYOCARDIUM; PROGNOSIS; RISK FACTORS; TENASCIN; TISSUE INHIBITOR OF METALLOPROTEINASE-1; VENTRICULAR DYSFUNCTION, LEFT;

EID: 84887148802     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2013.08.005     Document Type: Article

References (51)

1. P. Richardson, W. McKenna, and M. Bristow Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of cardiomyopathies Circulation 93 1996 841 842
2. E. Amiya, K. Tanabe, Y. Ikari, Y. Nakajima, and K. Hara Prolonged QRS duration and severity of mitral regurgitation are unfavorable prognostic markers of heart failure in patients with nonischemic dilated cardiomyopathy Circ J 70 2006 57 62
3. A. Bielecka-Dabrowa, M. Wierzbicka, M. Dabrowa, and A. Goch New methods in laboratory diagnostics of dilated cardiomyopathy Cardiol J 15 2008 388 395
4. H. Krum The Task Force for the diagnosis and treatment of chronic heart failure of the European Society of Cardiology. Guidelines for the diagnosis and treatment of chronic heart failure: full text (update 2005) Eur Heart J 26 2005 2472 [author reply 3-4]
5. Y. Kanzaki, F. Terasaki, and M. Okabe Myocardial inflammatory cell infiltrates in cases of dilated cardiomyopathy as a determinant of outcome following partial left ventriculectomy Jpn Circ J 65 2001 797 802
6. B.A. Groenning, I. Raymond, P.R. Hildebrandt, J.C. Nilsson, M. Baumann, and F. Pedersen Diagnostic and prognostic evaluation of left ventricular systolic heart failure by plasma N-terminal pro-brain natriuretic peptide concentrations in a large sample of the general population Heart 90 2004 297 303
7. B.J. Maron, J.A. Towbin, and G. Thiene Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention Circulation 113 2006 1807 1816
8. T.F. Ismail, S.K. Prasad, and D.J. Pennell Prognostic importance of late gadolinium enhancement cardiovascular magnetic resonance in cardiomyopathy Heart 98 2012 438 442
9. S.L. Bowers, I. Banerjee, and T.A. Baudino The extracellular matrix: at the center of it all J Mol Cell Cardiol 48 2010 474 482
10. M. Franz, B.R. Brehm, and P. Richter Changes in extra cellular matrix remodelling and re-expression of fibronectin and tenascin-C splicing variants in human myocardial tissue of the right atrial auricle: implications for a targeted therapy of cardiovascular diseases using human SIP format antibodies J Mol Histol 41 2010 39 50
11. C. Marchesi, F. Dentali, and E. Nicolini Plasma levels of matrix metalloproteinases and their inhibitors in hypertension: a systematic review and meta-analysis J Hypertens 30 2012 3 16
12. R.S. Velagaleti, P. Gona, and J. Sundstrom Relations of biomarkers of extracellular matrix remodeling to incident cardiovascular events and mortality Arterioscler Thromb Vasc Biol 30 2010 2283 2288
13. K. Imanaka-Yoshida, M. Hiroe, and T. Yoshida Interaction between cell and extracellular matrix in heart disease: multiple roles of tenascin-C in tissue remodeling Histol Histopathol 19 2004 517 525
14. M. Hiroe, K. Imanaka-Yoshida, and T. Yoshida The role of tenascin C in the development of myocardial remodeling Nippon Rinsho 65 Suppl. 4 2007 206 213
15. J.E. Schwarzbauer Fibronectin: from gene to protein Curr Opin Cell Biol 3 1991 786 791
16. L. Borsi, E. Balza, B. Gaggero, G. Allemanni, and L. Zardi The alternative splicing pattern of the tenascin-C pre-mRNA is controlled by the extracellular pH J Biol Chem 270 1995 6243 6245
17. A. Baldinger, B.R. Brehm, and P. Richter Comparative analysis of oncofetal fibronectin and tenascin-C expression in right atrial auricular and left ventricular human cardiac tissue from patients with coronary artery disease and aortic valve stenosis Histochem Cell Biol 135 2011 427 441
18. M. Franz, A. Berndt, and A. Altendorf-Hofmann Serum levels of large tenascin-C variants, matrix metalloproteinase-9, and tissue inhibitors of matrix metalloproteinases in concentric versus eccentric left ventricular hypertrophy Eur J Heart Fail 11 2009 1057 1062
19. M. Franz, D. Neri, and A. Berndt Chronic cardiac allograft rejection: critical role of ED-A(+) fibronectin and implications for targeted therapy strategies J Pathol 226 2012 557 561
20. J.N. Rybak, C. Roesli, M. Kaspar, A. Villa, and D. Neri The extra-domain A of fibronectin is a vascular marker of solid tumors and metastases Cancer Res 67 2007 10948 10957
21. C. Schliemann, and D. Neri Antibody-based vascular tumor targeting Recent Results Cancer Res 180 2010 201 216
22. U. Gabler, A. Berndt, and H. Kosmehl Matrix remodelling in dilated cardiomyopathy entails the occurrence of oncofetal fibronectin molecular variants Heart 75 1996 358 362
23. E. Herpel, M. Pritsch, A. Koch, T.J. Dengler, P. Schirmacher, and P.A. Schnabel Interstitial fibrosis in the heart: differences in extracellular matrix proteins and matrix metalloproteinases in end-stage dilated, ischaemic and valvular cardiomyopathy Histopathology 48 2006 736 747
24. F. Terasaki, H. Okamoto, and K. Onishi Higher serum tenascin-C levels reflect the severity of heart failure, left ventricular dysfunction and remodeling in patients with dilated cardiomyopathy Circ J 71 2007 327 330
25. N. Fujimoto, K. Onishi, and A. Sato Incremental prognostic values of serum tenascin-C levels with blood B-type natriuretic peptide testing at discharge in patients with dilated cardiomyopathy and decompensated heart failure J Card Fail 15 2009 898 905
26. L. Borsi, E. Balza, and B. Carnemolla Selective targeted delivery of TNFalpha to tumor blood vessels Blood 102 2003 4384 4392
27. A. Villa, E. Trachsel, and M. Kaspar A high-affinity human monoclonal antibody specific to the alternatively spliced EDA domain of fibronectin efficiently targets tumor neo-vasculature in vivo Int J Cancer 122 2008 2405 2413
28. A. Luk, E. Ahn, G.S. Soor, and J. Butany Dilated cardiomyopathy: a review J Clin Pathol 62 2009 219 225
29. F. Kuethe, H.H. Sigusch, and K. Hilbig Detection of viral genome in the myocardium: lack of prognostic and functional relevance in patients with acute dilated cardiomyopathy Am Heart J 153 2007 850 858
30. F. Kramer, and H. Milting Novel biomarkers in human terminal heart failure and under mechanical circulatory support Biomarkers 16 Suppl. 1 2011 S31 S41
31. A.L. Chancey, G.L. Brower, J.T. Peterson, and J.S. Janicki Effects of matrix metalloproteinase inhibition on ventricular remodeling due to volume overload Circulation 105 2002 1983 1988
32. J. Fielitz, M. Leuschner, and H.R. Zurbrugg Regulation of matrix metalloproteinases and their inhibitors in the left ventricular myocardium of patients with aortic stenosis J Mol Med 82 2004 809 820
33. F.G. Spinale, M.L. Coker, and L.J. Heung A matrix metalloproteinase induction/activation system exists in the human left ventricular myocardium and is upregulated in heart failure Circulation 102 2000 1944 1949
34. D. Reinhardt, H.H. Sigusch, J. Hensse, S.C. Tyagi, R. Korfer, and H.R. Figulla Cardiac remodelling in end stage heart failure: upregulation of matrix metalloproteinase (MMP) irrespective of the underlying disease, and evidence for a direct inhibitory effect of ACE inhibitors on MMP Heart 88 2002 525 530
35. Y.Y. Li, and A.M. Feldman Matrix metalloproteinases in the progression of heart failure: potential therapeutic implications Drugs 61 2001 1239 1252
36. M.H. Hessel, G.B. Bleeker, and J.J. Bax Reverse ventricular remodelling after cardiac resynchronization therapy is associated with a reduction in serum tenascin-C and plasma matrix metalloproteinase-9 levels Eur J Heart Fail 9 2007 1058 1063
37. M. Batlle, F. Perez-Villa, and E. Garcia-Pras Down-regulation of matrix metalloproteinase-9 (MMP-9) expression in the myocardium of congestive heart failure patients Transplant Proc 39 2007 2344 2346
38. S. Heymans, B. Schroen, and P. Vermeersch Increased cardiac expression of tissue inhibitor of metalloproteinase-1 and tissue inhibitor of metalloproteinase-2 is related to cardiac fibrosis and dysfunction in the chronic pressure-overloaded human heart Circulation 112 2005 1136 1144
39. C.V. Thomas, M.L. Coker, J.L. Zellner, J.R. Handy, A.J. Crumbley III, and F.G. Spinale Increased matrix metalloproteinase activity and selective upregulation in LV myocardium from patients with end-stage dilated cardiomyopathy Circulation 97 1998 1708 1715
40. F. Picard, M. Brehm, and M. Fassbach Increased cardiac mRNA expression of matrix metalloproteinase-1 (MMP-1) and its inhibitor (TIMP-1) in DCM patients Clin Res Cardiol 95 2006 261 269
41. P. Rouet-Benzineb, J.M. Buhler, and P. Dreyfus Altered balance between matrix gelatinases (MMP-2 and MMP-9) and their tissue inhibitors in human dilated cardiomyopathy: potential role of MMP-9 in myosin-heavy chain degradation Eur J Heart Fail 1 1999 337 352
42. J. George, S. Patal, D. Wexler, A. Roth, D. Sheps, and G. Keren Circulating matrix metalloproteinase-2 but not matrix metalloproteinase-3, matrix metalloproteinase-9, or tissue inhibitor of metalloproteinase-1 predicts outcome in patients with congestive heart failure Am Heart J 150 2005 484 487
43. Q. Yang, H.X. Wang, and Y.G. Zhao Expression of tissue inhibitor of metalloproteinase-4 (TIMP-4) in endometrium and placenta of rhesus monkey (Macaca mulatta) during early pregnancy Life Sci 78 2006 2804 2811
44. D.D. Bonnema, C.S. Webb, and W.R. Pennington Effects of age on plasma matrix metalloproteinases (MMPs) and tissue inhibitor of metalloproteinases (TIMPs) J Card Fail 13 2007 530 540
45. K. Imanaka-Yoshida, M. Hiroe, and Y. Yasutomi Tenascin-C is a useful marker for disease activity in myocarditis J Pathol 197 2002 388 394
46. A. Sato, K. Aonuma, and K. Imanaka-Yoshida Serum tenascin-C might be a novel predictor of left ventricular remodeling and prognosis after acute myocardial infarction J Am Coll Cardiol 47 2006 2319 2325
47. M. Franz, K. Grun, and P. Richter Extra cellular matrix remodelling after heterotopic rat heart transplantation: gene expression profiling and involvement of ED-A + fibronectin, alpha-smooth muscle actin and B + tenascin-C in chronic cardiac allograft rejection Histochem Cell Biol 134 2010 503 517
48. N. Aso, A. Tamura, and M. Nasu Circulating tenascin-C levels in patients with idiopathic dilated cardiomyopathy Am J Cardiol 94 2004 1468 1470
49. M. Franz, A. Berndt, and K. Grun Expression of extra domain A containing fibronectin in chronic cardiac allograft rejection J Heart Lung Transplant 30 2011 86 94
50. A.J. Booth, S.C. Wood, and A.M. Cornett Recipient-derived EDA fibronectin promotes cardiac allograft fibrosis J Pathol 226 2012 609 618
51. G. Casi, and D. Neri Antibody-drug conjugates: basic concepts, examples and future perspectives J Control Release 161 2012 422 428